A61K 2039/55
Medicinal preparations containing antigens or antibodies: characterised by the host/recipient
Official title: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
A61K2039/55 (Medicinal preparations containing antigens or antibodies: characterised by the host/recipient) appears on 2,561 US grants and 3,963 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,561
- Published applications
- 3,963
- Assignees
- 1,453
- Inventors
- 6,759
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 7 | 0 |
| 1977 | 11 | 0 |
| 1978 | 5 | 0 |
| 1979 | 3 | 0 |
| 1980 | 10 | 0 |
| 1981 | 7 | 0 |
| 1982 | 10 | 0 |
| 1983 | 3 | 0 |
| 1984 | 9 | 0 |
| 1985 | 10 | 0 |
| 1986 | 7 | 0 |
| 1987 | 13 | 0 |
| 1988 | 11 | 0 |
| 1989 | 9 | 0 |
| 1990 | 6 | 0 |
| 1991 | 18 | 0 |
| 1992 | 7 | 0 |
| 1993 | 11 | 0 |
| 1994 | 5 | 0 |
| 1995 | 12 | 0 |
| 1996 | 15 | 0 |
| 1997 | 23 | 0 |
| 1998 | 26 | 0 |
| 1999 | 31 | 0 |
| 2000 | 31 | 0 |
| 2001 | 22 | 9 |
| 2002 | 28 | 40 |
| 2003 | 33 | 63 |
| 2004 | 21 | 74 |
| 2005 | 28 | 57 |
| 2006 | 40 | 56 |
| 2007 | 40 | 83 |
| 2008 | 49 | 103 |
| 2009 | 37 | 125 |
| 2010 | 59 | 122 |
| 2011 | 56 | 131 |
| 2012 | 53 | 102 |
| 2013 | 66 | 144 |
| 2014 | 94 | 145 |
| 2015 | 100 | 182 |
| 2016 | 127 | 210 |
| 2017 | 153 | 246 |
| 2018 | 183 | 203 |
| 2019 | 154 | 252 |
| 2020 | 164 | 241 |
| 2021 | 163 | 248 |
| 2022 | 141 | 260 |
| 2023 | 125 | 245 |
| 2024 | 109 | 250 |
| 2025 | 130 | 219 |
| 2026 | 86 | 153 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Subcutaneous formulations of daratumumab and their uses in treating multiple myeloma22 Sep 2026US 12,742,018 B2Janssen Biotech, Inc.
- Subcutaneous formulations of daratumumab and their uses in treating multiple myeloma15 Sep 2026US 12,735,501 B2Janssen Biotech, Inc.
- Coronavirus vaccines compositions and method of using same8 Sep 2026US 12,728,159 B2Loyola University of Chicago
- Immune priming to accelerate/enhance immune response through administration of natural immune modulator1 Sep 2026US 12,721,889 B2ZIVO Bioscience, Inc.
- Anti-PD-1 antibodies for treatment of lung cancer25 Aug 2026US 12,715,921 B2Regeneron Pharmaceuticals, Inc.
- Compositions and methods for generating immunity to bacterial infection8 Oct 2026US 2026/0306601 A1Syntiron LLC
- Method for inducing an immune response8 Oct 2026US 2026/0306617 A1Acclarent, Inc.
- A vaccine against erysipelothrix rhusiopathiae and porcine parvo virus8 Oct 2026US 2026/0306618 A1Intervet Inc.
- Pediatric dosage and administration of anti-c5 antibodies for treatment of complement disorders8 Oct 2026US 2026/0308238 A1Alexion Pharmaceuticals, Inc.
- Orally-delivered vaccines for domesticated and wild animals to prevent pathogen spread using recombinant probiotic bacteria1 Oct 2026US 2026/0295027 A1
Most cited
By later US patents
- Antigenically active amino acid sequences190US 4,708,871 ACommonwealth Serum Laboratories Commission · 1987
- Human cytomegalovirus RNA vaccines130US 10,064,935 B2ModernaTX, Inc. · 2018
- System and method for measuring animals128US 8,036,429 B22011
- European vaccine strains of the porcine reproductive and respiratory syndrome virus110US 5,925,359 AAkzo Nobel N. V. · 1999
- Avirulent microbes and uses therefor: Salmonella typhi109US 5,387,744 AWashington University · 1995